WORLD JOURNAL OF ADVANCE
HEALTHCARE RESEARCH

Sana Jum*, Hamid Suleiman and Jamal Khadam

ABSTRACT

Background: Recently, it was noted that the spread of superficial fungal infections with widespread resistance to various antifungal drugs used in the traditional dose, with an increase in relapse rates, which caused a real medical problem due to the skin manifestations and clinical symptoms (itching) disturbing to the patient. Objectives: This study was designed to evaluate and compare the efficacy of oral terbinafine versus itraconazole in the treatment of Tinea Corporis and Tinea Cruris. Materials and Methods: This was a prospective, randomized comparative study. It was conducted at Tishreen University Hospital, Lattakia, during the period between 2022-2023. The study included 90 patients. After confirming the diagnosis, the patients were randomly divided into two groups. The first group: 45 patients treated with terbinafine orally at a dose of 500 mg daily for 4 weeks. The second group: 45 patients who were treated with itraconazole orally at a dose of 200 mg daily for 4 weeks. Results: There were statistically significant differences between the two research groups regarding the evaluation of recovery between the two research groups, where we find that the cases of complete recovery amounted to 86.7% in the oral itraconazole treatment group compared to 72.7% in the terbinafine group. Conclusion: Itraconazole is better than terbinafine in the treatment of Tinea Corporis and Tinea Cruris and can be considered as the first line. The safety of both drugs, even after using higher concentrations and a longer treatment period.

[Full Text Article] [Download Certificate]